These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

661 related articles for article (PubMed ID: 21917518)

  • 61. EndoPredict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer.
    Bertucci F; Finetti P; Viens P; Birnbaum D
    Cancer Lett; 2014 Dec; 355(1):70-5. PubMed ID: 25218596
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Topoisomerase IIalpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study.
    Kanta SY; Yamane T; Dobashi Y; Mitsui F; Kono K; Ooi A
    Hum Pathol; 2006 Oct; 37(10):1333-43. PubMed ID: 16949920
    [TBL] [Abstract][Full Text] [Related]  

  • 63. ER, HER2, and TOP2A expression in primary tumor, synchronous axillary nodes, and asynchronous metastases in breast cancer.
    Jensen JD; Knoop A; Ewertz M; Laenkholm AV
    Breast Cancer Res Treat; 2012 Apr; 132(2):511-21. PubMed ID: 21667123
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Predictive factors for anthracycline-based chemotherapy for human breast cancer.
    Miyoshi Y; Kurosumi M; Kurebayashi J; Matsuura N; Takahashi M; Tokunaga E; Egawa C; Masuda N; Kono S; Morimoto K; Kim SJ; Okishiro M; Yanagisawa T; Ueda S; Taguchi T; Tamaki Y; Noguchi S
    Breast Cancer; 2010 Apr; 17(2):103-9. PubMed ID: 19657712
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples.
    Mueller RE; Parkes RK; Andrulis I; O'Malley FP
    Genes Chromosomes Cancer; 2004 Apr; 39(4):288-97. PubMed ID: 14978790
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Topoisomerase II-alpha gene deletion is not frequent as its amplification in breast cancer.
    Park K; Han S; Gwak GH; Kim HJ; Kim J; Kim KM
    Breast Cancer Res Treat; 2006 Aug; 98(3):337-42. PubMed ID: 16502015
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours.
    Fleischmann A; Rotzer D; Seiler R; Studer UE; Thalmann GN
    Eur Urol; 2011 Aug; 60(2):350-7. PubMed ID: 21640482
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial.
    Ginzac A; Molnar I; Durando X; Motte Rouge T; Petit T; D'hondt V; Campone M; Bonichon-Lamichhane N; Venat Bouvet L; Levy C; Augereau P; Pistilli B; Arsene O; Jouannaud C; Nguyen S; Cayre A; Tixier L; Mahier Ait Oukhatar C; Nabholtz JM; Penault-Llorca F; Mouret-Reynier MA
    Breast Cancer Res Treat; 2024 Jun; 205(2):267-279. PubMed ID: 38453781
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The predictive and prognostic significance of pre- and post-treatment topoisomerase IIα in anthracycline-based neoadjuvant chemotherapy for local advanced breast cancer.
    Chen S; Huang L; Liu Y; Chen CM; Wu J; Shao ZM
    Eur J Surg Oncol; 2013 Jun; 39(6):619-26. PubMed ID: 23473851
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Prognostic and predictive value of the combination of TOP2A and HER2 in node-negative tumors 2 cm or smaller (T1N0) breast cancer.
    Zhong W; Yang Y; Zhang A; Lin W; Liang G; Ling Y; Zhong J; Yong J; Liu Z; Tian Z; Lin Q; Luo Q; Li Y; Gong C
    Breast Cancer; 2020 Nov; 27(6):1147-1157. PubMed ID: 32780321
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Are HER2 and TOP2A useful as prognostic or predictive biomarkers for anthracycline-based adjuvant chemotherapy for breast cancer?
    Pritchard KI
    J Clin Oncol; 2009 Aug; 27(24):3875-6. PubMed ID: 19620479
    [No Abstract]   [Full Text] [Related]  

  • 72. Tumour topoisomerase II alpha protein expression and outcome after adjuvant dose-dense anthracycline-based chemotherapy.
    Nikolényi A; Uhercsák G; Csenki M; Hamar S; Csörgo E; Tánczos E; Thurzó L; Brodowicz T; Wagnerova M; Kahán Z
    Pathol Oncol Res; 2012 Jan; 18(1):61-8. PubMed ID: 21681601
    [TBL] [Abstract][Full Text] [Related]  

  • 73. New understanding of the role of anthracyclines in early-stage breast cancer: patient selection considerations.
    Gennari A; Pronzato P
    Clin Breast Cancer; 2008 Dec; 8 Suppl 4():S179-83. PubMed ID: 19158039
    [TBL] [Abstract][Full Text] [Related]  

  • 74. HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide.
    Di Leo A; Larsimont D; Gancberg D; Jarvinen T; Beauduin M; Vindevoghel A; Michel J; Focan CH; Ries F; Gobert PH; Closon-Dejardin MT; Dolci S; Rouas G; Paesmans M; Lobelle JP; Isola J; Piccart MJ
    Ann Oncol; 2001 Aug; 12(8):1081-9. PubMed ID: 11583189
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment.
    Bouchalova K; Cizkova M; Cwiertka K; Trojanec R; Hajduch M
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2009 Mar; 153(1):13-7. PubMed ID: 19365520
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Underpinning the repurposing of anthracyclines towards colorectal cancer: assessment of topoisomerase II alpha gene copy number alterations in colorectal cancer.
    Nygård SB; Christensen IJ; Smith DH; Nielsen SL; Jensen NF; Nielsen HJ; Vainer B; Brünner N
    Scand J Gastroenterol; 2013 Dec; 48(12):1436-43. PubMed ID: 24138107
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Topoisomerase II alpha and microtubule-associated protein-tau as a predictive marker in axillary lymph node positive breast cancer.
    Won HS; Lee KE; Sung SH; Choi MY; Jo JY; Nam EM; Mun YC; Seong CM; Lee SN
    Tumori; 2014; 100(1):80-6. PubMed ID: 24675496
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Prognostic, predictive abilities and concordance of BCL2 and TP53 protein expression in primary breast cancers and axillary lymph-nodes: a retrospective analysis of the Belgian three arm study evaluating anthracycline vs CMF adjuvant chemotherapy.
    Bozovic-Spasojevic I; Ameye L; Paesmans M; Larsimont D; Di Leo A; Dolci S; Piccart M; de Azambuja E; Loi S
    Breast; 2014 Aug; 23(4):473-81. PubMed ID: 24768477
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Prognostic Significance of VEGFC and VEGFR1 mRNA Expression According to HER2 Status in Breast Cancer: A Study of Primary Tumors from Patients with High-risk Early Breast Cancer Participating in a Randomized Hellenic Cooperative Oncology Group Trial.
    Linardou H; Kalogeras KT; Kronenwett R; Alexopoulou Z; Wirtz RM; Zagouri F; Scopa CD; Gogas H; Petraki K; Christodoulou C; Pavlakis K; Koutras AK; Samantas E; Patsea H; Pectasides D; Bafaloukos D; Fountzilas G
    Anticancer Res; 2015 Jul; 35(7):4023-36. PubMed ID: 26124351
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013.
    Harris LN; Broadwater G; Abu-Khalaf M; Cowan D; Thor AD; Budman D; Cirrincione CT; Berry DA; Winer EP; Hudis CA; Hayes DF; Friedman P; Ellis M; Dressler L
    J Clin Oncol; 2009 Jul; 27(21):3430-6. PubMed ID: 19470942
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.